BLUE Insider Trading Activity and SEC Form 4 Filings
BLUE insider trading summary
No open-market insider purchases or sales of bluebird bio, Inc. (BLUE) have been reported on SEC Form 4 in the past 12 months.
Latest BLUE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 3, 2025 | Andrew Obenshain | President and CEO | Sell | $4K (921 @ $3.92) |
| Mar 3, 2025 | Richard A Colvin | Chief Medical Officer | Sell | $2K (584 @ $3.92) |
| Mar 3, 2025 | Thomas J Klima | See Remarks | Sell | $2K (500 @ $3.92) |
| Feb 3, 2025 | Andrew Obenshain | President and CEO | Sell | $636 (86 @ $7.39) |
| Feb 3, 2025 | Richard A Colvin | Chief Medical Officer | Sell | $473 (64 @ $7.39) |
| Feb 3, 2025 | Joseph Vittiglio | Chief Business & Legal Officer | Sell | $2K (238 @ $7.39) |
| Feb 3, 2025 | Thomas J Klima | See Remarks | Sell | $902 (122 @ $7.39) |
| Jan 6, 2025 | Richard A Colvin | Chief Medical Officer | Sell | $176 (19 @ $9.24) |
| Jan 6, 2025 | Andrew Obenshain | President and CEO | Sell | $1K (140 @ $9.24) |
| Dec 10, 2024 | Richard A Colvin | Chief Medical Officer | Sell | $1K (2,824 @ $0.42) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.